Orchid in development deal with Merck
India's Orchid Chemicals and Pharmaceuticals says it has struck a development deal with Merck for the discovery anti-infective drugs. That pact has the potential to earn more than $100 million for Orchid. The upfront payment was undisclosed. Orchid release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
